Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate Inobrodib in Combination with Pomalidomide and Dexamethasone Versus Standard Available Therapy in Patients with Relapsed or Refractory Multiple Myeloma'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National University Hospital
Singapore General Hospital
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Chng Wee Joo
Dr Chandramouli Nagarajan
Dr Allison Tso
Published by HT Digital Content Services with permission from Health Daily Digest....